| 4.28 -0.04 (-0.93%) | 10-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.38 | 1-year : | 5.78 |
| Resists | First : | 4.6 | Second : | 4.94 |
| Pivot price | 4.22 |
|||
| Supports | First : | 4.05 | Second : | 3.36 |
| MAs | MA(5) : | 4.25 |
MA(20) : | 4.27  |
| MA(100) : | 4.64 |
MA(250) : | 4.51 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 69.9 |
D(3) : | 52.6 |
| RSI | RSI(14): 42.9 |
|||
| 52-week | High : | 5.44 | Low : | 3.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ABUS ] has closed below upper band by 28.5%. Bollinger Bands are 63.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.38 - 4.4 | 4.4 - 4.42 |
| Low: | 4.18 - 4.2 | 4.2 - 4.22 |
| Close: | 4.24 - 4.28 | 4.28 - 4.31 |
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Mon, 05 Oct 2026
At $5 a share, Arbutus Biopharma (ABUS) accepts tendered shares; Roivant retains about 19.5%. - Stock Titan
Thu, 01 Oct 2026
The share offer capped at $230M has expired. Arbutus (ABUS) announces final results. - Stock Titan
Wed, 30 Sep 2026
Arbutus Biopharma (ABUS) Shares Rise on $230M Share Buyback Comp - GuruFocus
Fri, 21 Aug 2026
Arbutus (NASDAQ: ABUS) plans Dutch auction share buyback - Stock Titan
Fri, 21 Aug 2026
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan - Yahoo Finance
Mon, 10 Aug 2026
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 153 (M) |
| Shares Float | 151 (M) |
| Held by Insiders | 15.9 (%) |
| Held by Institutions | 67.2 (%) |
| Shares Short | 34,050 (K) |
| Shares Short P.Month | 18,920 (K) |
| EPS | 0.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.3 |
| Profit Margin | 84.2 % |
| Operating Margin | -567.2 % |
| Return on Assets (ttm) | 48.8 % |
| Return on Equity (ttm) | 89.5 % |
| Qtrly Rev. Growth | -90.6 % |
| Gross Profit (p.s.) | 1.06 |
| Sales Per Share | 1.18 |
| EBITDA (p.s.) | 0.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -80 (M) |
| PE Ratio | 5.41 |
| PEG Ratio | 0 |
| Price to Book value | 3.26 |
| Price to Sales | 3.61 |
| Price to Cash Flow | -26.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|